Clinical trials: Pulmonary Disorder
Lung Cancer
Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00407550
- Testing
- gemcitabine HCL, pemetrexed disodium
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
COVID-19, Bariatric Surgery Candidate
Bariatric Surgery and COVID-19
The National Bariatric Surgical Registry (NBSR) is a prospectively collected database for all patients undergoing elective bariatric surgery in the UK.
- Trial name
- NCT05532891
- Testing
- COVID-19 pandemic
- Where
- United Kingdom
- Volunteers
- 11,545 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Intubated Infants Were Intend to Extubation Using Noninvasive Ventilation Strategies
A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation
Respiratory distress syndrome (RDS) is the main cause of respiratory failure in preterm neonates, its incidence varying from 80% to 25% depending on gestational age.When optimal prenatal care is provided, the best approach to…
- Trial name
- NCT03181958
- Testing
- NHFOV, NCPAP, NIPPV
- Where
- China
- Volunteers
- 1,493 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
COVID-19, Children With Medical Complexity (CMC)
ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance
The purpose of this research study is to learn about the factors parents consider when deciding whether their child will go to school in-person or attend from home.
- Trial name
- NCT04895085
- Testing
- BinaxNOW Rapid Antigen System
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Small Cell Lung Cancer
Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer
This is a phase II, two-stage, open-label, single-agent study of the experimental drug RAD001 (everolimus) in patients with previously treated small cell lung cancer. RAD001 will be administered orally at a dose of 10 mg daily.
- Trial name
- NCT00374140
- Testing
- RAD001 (everolimus)
- Where
- 19 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ahmad Tarhini
Asthma
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the…
- Trial name
- UNIK (NCT01167010)
- Testing
- Formoterol/Budesonide, Foraseq, Alenia
- Where
- 5 sites in Brazil
- Volunteers
- 552 people
- Sponsor
- Eurofarma Laboratorios S.A.
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Bronchopulmonary Dysplasia of Newborn
Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia
This is a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study of sildenafil in premature infants (inpatient in Neonatal Intensive Care Units (NICUs)) with severe bronchopulmonary…
- Trial name
- SILDI-SAFE (NCT04447989)
- Testing
- Sildenafil
- Where
- 25 sites in United States
- Volunteers
- 125 people
- Sponsor
- Christoph Hornik
Pneumonia
Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application
The Curetis Unyvero LRT55 Application is intended to detect and to identify genes of 21 microorganisms and 19 genes associated with antibiotic resistance in 4 hours.
- Trial name
- LRT55 (NCT01922024)
- Testing
- LRT55 Testing
- Where
- 9 sites in United States
- Volunteers
- 2,124 people
- Sponsor
- Curetis GmbH
Vasculitis
Belimumab in Remission of VASculitis
The purpose of this study is to evaluate the efficacy and safety of belimumab, in combination with azathioprine, for the maintenance of remission following a standard induction regimen in patients with Wegener's granulomatosis or…
- Trial name
- BREVAS (NCT01663623)
- Testing
- Belimumab 10 mg/kg, Azathioprine
- Where
- 89 sites in United States, Australia and 18 more
- Volunteers
- 106 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Pulmonary Disease, Chronic Obstructive
Advancing Symptom Alleviation With Palliative Treatment
Chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD), and interstitial lung disease (i.e., pulmonary fibrosis) are common serious illnesses.
- Conditions
- Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- ADAPT (NCT02713347)
- Testing
- ADAPT Intervention
- Where
- 2 sites in United States
- Volunteers
- 306 people
- Sponsor
- VA Office of Research and Development
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease
Lenalidomide for Adult Histiocyte Disorders
This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).
- Conditions
- Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
- Trial name
- NCT02523040
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
SARS-CoV-2 Infection, COVID-19
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.
- Trial name
- NCT05997290
- Testing
- BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1), BNT162b2 (Omi KP.2)
- Where
- 37 sites in United States
- Volunteers
- 1,051 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.